Aditxt, Inc. announced that its subsidiary, Adimune, has successfully completed preclinical efficacy and safety studies for its immune modulation therapeutic platform, with presentation materials available on Adimune's website.
AI Assistant
ADITXT INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.